间歇性与持续性雄激素阻断治疗晚期前列腺癌临床分析

目的探讨最大限度雄激素阻断（MAB）和间歇内分泌疗法（IHT）治疗晚期前列腺癌的疗效及副作用，为临床治疗晚期前列腺癌提供依据。方法2006年1月至2010年1月我院共收治晚期前列腺癌患者90例，其中48例予比卡鲁胺联合手术去势的MAB治疗、42例予戈舍瑞林联合比卡鲁胺行IHT治疗。结果与MAB疗法相比，IHT疗法副作用小，治疗间歇期未加重肿瘤进展。结论IHT疗法与MAB疗法治疗晚期前列腺癌的疗效无统计学差异，而IHT疗法安全、可行、副作用小，可作为雄激素依赖性晚期前列腺癌内分泌治疗的首选。

Intermittent and persistent androgen deprivation treatment of advanced prostate cancer

Objective To evaluate the efficacy and side effect on the maximum androgen bloekade（MAB）and intermittent hormonal therapy （]HT）in patient with advanced prostate cancer and Provide a theoretical basis and experimental basis for the treatment of advanced prostate cancer. Methods 90 cases of advanced prostate cancer patients between 48 patients who were taken MAB treatment and 42 patients who were taken IHT treatment. Results Through the comparison with the MAB treatment IHT treatment side effects is small, the treatment of intermittent period did not increase tumor progression. Conelusion In advanced prostate cancer, compared with the group subjects who were taken surgical castration combined with Bicalutamide for maximum androgen blockage（MAB）, the treatment effect not worse than the patients who were taken intermittent hormonal therapy （IHT）combined with goserelin and Bicalutamide. the intermittent hormonal therapy （1HT）is safety and feasible. Thus,IHT for androgen-dependent advanced prostate cancer will be a first line of treatment choice.